Brief: Proqr Announces Axiomer Rna Editing Licensing And Research Collaboration With Lilly

ProQR Therapeutics NV

08/09/2021 21:16

Sept 8 (Reuters) - ProQR Therapeutics NV  PRQR.O :
    * PROQR ANNOUNCES AXIOMER® RNA EDITING LICENSING AND
RESEARCH
COLLABORATION WITH LILLY
    * PROQR THERAPEUTICS NV - PROQR TO RECEIVE $50 MILLION
CONSISTING
OF UPFRONT PAYMENT AND EQUITY INVESTMENT
    * PROQR - COMPANIES WILL COLLABORATE TO DEVELOP EDITING
OLIGONUCLEOTIDES DIRECTED TO UP TO FIVE TARGETS USING PROQR'S
AXIOMER RNA EDITING PLATFORM
    * PROQR - PROQR IS ELIGIBLE TO ADDITIONALLY RECEIVE UP TO
ABOUT
$1.25 BILLION IN RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION
MILESTONES, PLUS ROYALTIES
    * PROQR - PROQR WILL RECEIVE $50 MILLION CONSISTING OF AN
UPFRONT
PAYMENT OF $20 MILLION, AS WELL AS AN EQUITY INVESTMENT IN ITS
ORDINARY SHARES OF $30 MILLION

Source text for Eikon:  ID:nGNXbgr116 
Further company coverage:  PRQR.O 

 ((Reuters.Briefs@thomsonreuters.com;))